Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha

Journal of Molecular Modeling

Volumn 20, Issue 8, 2014, Pages

  Chakraborty, Sandipan ^a,b   Biswas, Pradip Kumar ^a  

^a TOUGALOO COLLEGE   (United States)

^b Saroj Mohan Institute of Technology   (India)

Author keywords

ER transactivation; Estrogen receptor alpha (ER ); In silico studies; Tamoxifen resistance

Indexed keywords

DIETHYLSTILBESTROL; DIMER; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; TAMOXIFEN; ESTROGEN RECEPTOR ALPHA, HUMAN; LIGAND; REPRESSOR PROTEIN;

ARTICLE; COMPUTER MODEL; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG RECEPTOR BINDING; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; STRUCTURE ACTIVITY RELATION; AGONISTS; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLUSTER ANALYSIS; COMPUTER SIMULATION; HUMAN; MOLECULAR DOCKING; PRINCIPAL COMPONENT ANALYSIS; PROTEIN MULTIMERIZATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; THERMODYNAMICS;

CLUSTER ANALYSIS; COMPUTER SIMULATION; ESTROGEN RECEPTOR ALPHA; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PRINCIPAL COMPONENT ANALYSIS; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; REPRESSOR PROTEINS; TAMOXIFEN; THERMODYNAMICS;

EID: 84904518440     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-014-2338-x     Document Type: Article

References (44)

1. World Cancer Report (2008) International Agency for Research on Cancer. http://www.iarc.fr/en/publications/pdfs-online/wcr/
2. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y (1987) Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47:4355-4360 (Pubitemid 17128144)
3. Ip M, Milholland RJ, Rosen F, Kim U (1979) Mammary cancer: selective action of the estrogen receptor comple. Science 203: 361-363 (Pubitemid 9118918)
4. Andersen J, Poulsen HS (1989) Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer. Cancer 64: 1901-1908 (Pubitemid 19267811)
5. Beato M, Herrlich P, Schutz G (1995) Steroid hormone receptors: many actors in search of a plot. Cell 83:851-857 (Pubitemid 26006527)
6. Levin ER (2001) Cell localization, physiology, and nongenomic actions of estrogen receptors. J Appl Physiol 91:1860-1867
7. Vidal O, Lindberg M, Sävendahl L, Lubahn DB, Ritzen EM, Gustafsson JÅ, Ohlsson C (1999) Disproportional Body Growth in Female Estrogen Receptor-α-inactivated Mice. Biochem Biophys Res Commun 265:569-571
8. Stender JD, Kim K, Charn TH, Komm B, Chang KCN, Kraus WL, Benner C, Glass CK, Katzenellenbogen BS (2010) Genomewide analysis of estrogen receptor α DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol 30:3943-3955
9. Ruff M, Gangloff M, Wurtz JM, Moras D (2000) Estrogen receptor transcription and transactivation. Structure-function relationship in DNA- and ligand-binding domains of estrogen receptors. Breast Cancer Res 2:353-359 (Pubitemid 32223618)
10. Nadal A, Diaz M, Valverde MA (2001) The estrogen trinity: membrane, cytosolic, and nuclear effects. News Physiol Sci 16:251-255 (Pubitemid 33575264)
11. Bjornstrom L, Sjoberg M (2005) Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19:833-842 (Pubitemid 40397050)
12. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758 (Pubitemid 27458965)
13. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL (1998) The structural basis of estrogen receptor/ coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937 (Pubitemid 29019045)
14. Howell A, Osborne CK, Morris C, Wakeling AE (2000) ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 89:817-825 (Pubitemid 30658581)
15. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. New Engl J Med 339:1609-1618
16. Riggs BL, Hartmann LC (2003) Selective estrogen-receptor modulators- mechanisms of action and application to clinical practice. New Engl J Med 348:618-629 (Pubitemid 36210865)
17. Lewis JS, Jordan VC (2005) Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance. Mutat Res 591:247-263 (Pubitemid 41654853)
18. Legault-Poisson S, Jolivet J, Poisson R, Beretta-Piccoli M, Ban PR (1979) Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat Rep 63:1839-1841 (Pubitemid 10138940)
19. Dorssers LCJ, Agthoven TV, Dekker A, Agthoven TLAV, Kok EM (1993) Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bcar-1, a common integration site. Mol Endocrinol 7: 870-878 (Pubitemid 23220637)
20. Dorssers LCJ, Flier SVD, Brinkman A, Agthoven TV, Veldscholte J, Berns EMJJ, Klijn JGM, Beex LVAM, Foekens JA (2001) Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 61:1721-1733 (Pubitemid 32980504)
21. Nicholson RI, Hutcheson IR, Britton D, Knowlden JM, Jones HE, Harper ME, Hiscox SE, Barrow D, Gee JM (2005) Growth factor signaling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J Steroid Biochem Mol Biol 93: 257-262 (Pubitemid 40602498)
22. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jallank K, Floore A, Velds A, Veer LV, Neefjes J (2004) Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 5: 597-605 (Pubitemid 38748921)
23. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R (2004) Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935 (Pubitemid 38868139)
24. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG, Rose DW (1998) Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95:2920-2925
25. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815 (Pubitemid 24007801)
26. Humphrey W, Dalke A, Schulten K (1996) VMD - Visual Molecular Dynamics. J Mol Graph 14:33-38
27. Berendsen HJC, Spoel DVD, Drunen RV (1995) GROMACS: a message-passing parallel molecular dynamics implementation. Comp Phys Commun 91:45-56
28. Lindahl E, Hess B, Spoel DVD (2001) GROMACS 3.0 a package for molecular simulation and trajectory analysis. J Mol Model 7: 306-317 (Pubitemid 36153547)
29. Jorgensen WL, Rives T (1988) Development and testing of the OPLS all-atom force field on conformational energetic and properties of organic liquids. J Am Chem Soc 110:1657-1666
30. Arnold K, Bordoli L, Kopp J, Schwede T (2006) The SWISS-MODEL Workspace: a web based environment for protein structure modeling. Bioinformatics 22:195-201 (Pubitemid 43205406)
31. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) Automated docking using a Lamarkian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639-1662 (Pubitemid 128590223)
32. Car R, Parrinello M (1985) Unified approach formolecular dynamics and density functional theory. Phys Rev Lett 55:2471-2474
33. Hess B, Bekker H, Berendsen HJC, Fraaije JGEM (1997) LINCS: A linear constraint solver for molecular simulations. J Comp Chem 18: 1463-1472 (Pubitemid 127637344)
34. Kabsch W, Sander C (1983) Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22:2577-2637
35. Tuncbag N, Gursoy A, Keskin O (2009) Identification of computational hotspots in protein interfaces: combining solvent accessibility and inter-residue potential improves the accuracy. Bioinformatics 25: 1513-1520
36. Laurie AT, Jackson RM (2005) Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 21:1908-1916 (Pubitemid 40668026)
37. Lyskov S, Gray JJ (2008) The RosettaDock server for local protein-protein docking. Nucleic Acid Res 36:W233-W238
38. Chakraborty S, Cole S, Rader N, King C, Rajnarayanan RV, Biswas PK (2012) In silico design of peptidic inhibitors targeting Estrogen Receptor alpha dimer interface. Mol Divers 16:441-451
39. Varlakhanova N, Snyder C, Jose S, Hahm JB, Privalsky ML (2010) Estrogen receptors recruit SMRT and N-CoR corepressor through newly recognized contacts between the compressor N-terminus and the receptor DNA binding domain. Mol Cell Biol 30:1434-1445
40. Heldring N, Pawson T, McDonnell D, Treuter E, Gustafsson JA, Pike ACW (2007) Structural insights into corepressor recognition by antagonist-bound estrogen receptors. J Biol Chem 282:10449-10455 (Pubitemid 47096592)
41. Hu X, Li Y, Lazar MA (2001) Determinants of CoRNR-dependent repression complex assembly on nuclear hormone receptors. Mol Cell Biol 21:1747-1758 (Pubitemid 32156395)
42. Tamrazi A, Carlson KE, Daniels JR, Hurth KM, Katzenellenbogen JA (2002) Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate. Mol Endocrinol 16: 2706-2719 (Pubitemid 36020652)
43. Pike ACW, Brzozowski AM, Walton J, Hubbard RE, Thorsell A-G, Li Y-L, Gustafsson J-A, Carlquist M (2001) Structural insights into the mode of action of a pure antiestrogen. Structure 9:145-153 (Pubitemid 32215278)
44. Chan CM, Lykkesfeldt AE, Parker MG, Dowsett M (1999) Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer. Clin Cancer Res 5:3460-3467